Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (e+)" rating reiterated by Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

FDMT has been the subject of a number of other research reports. HC Wainwright reaffirmed a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Chardan Capital decreased their target price on 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a report on Friday, May 9th. Bank of America decreased their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a report on Monday, March 10th. The Goldman Sachs Group decreased their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Barclays decreased their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $29.56.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ FDMT opened at $3.84 on Friday. 4D Molecular Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $28.93. The company has a market cap of $177.91 million, a PE ratio of -1.21 and a beta of 2.84. The business has a 50-day simple moving average of $3.70 and a two-hundred day simple moving average of $4.31.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. On average, sell-side analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in FDMT. Rhumbline Advisers increased its position in shares of 4D Molecular Therapeutics by 5.3% in the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock valued at $409,000 after buying an additional 3,675 shares in the last quarter. Proficio Capital Partners LLC increased its position in shares of 4D Molecular Therapeutics by 100.0% in the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock valued at $111,000 after buying an additional 10,000 shares in the last quarter. M&T Bank Corp increased its position in shares of 4D Molecular Therapeutics by 98.9% in the fourth quarter. M&T Bank Corp now owns 37,487 shares of the company's stock valued at $209,000 after buying an additional 18,639 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at approximately $629,000. Finally, PNC Financial Services Group Inc. increased its position in shares of 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock valued at $51,000 after buying an additional 3,630 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.